To address this problem, we engineered a novel Exo‐based delivery system, termed cmExoaCD11b, designed to activate the STING signaling, reprogram tumor‐associated macrophages (TAMs), reducing the tumor immunosuppression in TME. This evidence concerns the gene STING1 and neoplasm.